NICE rejects Alzheimer's drug donanemab owing to cost and "significant health risks". Mahase E. BMJ 2024;387:q2342.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mahase E. NICE rejects Alzheimer's drug donanemab owing to cost and "significant health risks". BMJ 2024;387:q2342.
PMID: 39442962